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Abstract
Introduction: The purpose of the present study was to investigate the relationship of expression of hypoxia inducible
factor (HIF)-1a-modifying enzymes prolyl hydroxylase (PHD)1, PHD2 and PHD3 to response of tumours and survival in
breast cancer patients enrolled in a phase II trial of neoadjuvant anthracycline and tamoxifen therapy.
Methods: The expression of PHD1, PHD2 and PHD3 together with HIF-1a and the HIF-inducible genes vascular
endothelial cell growth factor (VEGF) and carbonic anhydrase IX were assessed by immunohistochemistry using a
tissue microarray approach in 211 patients with T2-4 N0-1 breast cancer enrolled in a randomised trial comparing
single-agent epirubicin versus epirubicin and tamoxifen as the primary systemic treatment.
Results: PHD1, PHD2 and PHD3 were detected in 47/179 (26.7%), 85/163 (52.2%) and 69/177 (39%) of tumours at
baseline. PHD2 and PHD3 expression was moderate/strong whereas PHD1 expression was generally weak. There
was a significant positive correlation between HIF-1a and PHD1 (P = 0.002) and PHD3 (P < 0.05) but not PHD2
(P = 0.41). There was a significant positive relationship between VEGF and PHD1 (P < 0.008) and PHD3 (P = 0.001)
but not PHD2 (P = 0.09). PHD1, PHD2 and PHD3 expression was significantly increased after epirubicin therapy (all
P < 0.000) with no significant difference in PHD changes between the treatment arms. There was no significant
difference in response in tumours that expressed PHDs and PHD expression was not associated with survival.
Conclusions: Although expression of the PHDs was not related to response or survival in patients receiving
neoadjuvant epirubicin, our data provide the first evidence that these enzymes are upregulated on therapy in
breast cancer and that the biological effects independent of HIF make them therapeutic targets.
Introduction
The hypoxic response through hypoxia inducible factor
(HIF) is recognised as one of the most important micro-
environmental influences on tumour behaviour that
enables tumours to acquire an aggressive phenotype and
become resistant to both chemotherapy and radiotherapy
[1,2]. Although HIF-1a is transcribed continuously, in
normoxia its levels are kept low by a rapid degradation
process through the ubiquitin-proteasome system [3].
T h i sp r o c e s si sa c h i e v e dt h r o u g hh y d r o x y l a t i o no ft w o
prolyl residues at Pro-402 and Pro-564 in the oxygen-
dependent HIF-1a [4], and leads to recognition by the
von Hippel-Lindau tumour suppressor protein and tar-
geting for degradation [5]. Three isoenzymes - prolyl
hydroxylase (PHD)1, PHD2 and PHD3 - are responsible
for the modification of HIF-1a, the activity of which is
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together with iron, ascorbate and 2-oxoglutarate as
essential co-factors [6]. Therefore as the abundance of
molecular oxygen for hydroxylation decreases, which
occurs in the hypoxic microenvironment of a tumour
with its disordered and leaky vasculature, a reduction in
PHD enzymatic activity occurs, allowing HIF-1a accu-
mulation. HIF-1a is then able to translocate to the
nucleus, where it dimerises with its constitutively
expressed partner HIF-1b (also known as aryl nuclear
hydrocarbon translocator) and then binds to the hypoxic
response element of genes that enhance tumour cell sur-
v i v a ls u c ha sg l y c o l y s i s( G l u t 1 ) ,a n g i o g e n e s i s( f o re x a m -
ple, vascular endothelial growth factor (VEGF)), iron
metabolism (transferrin), pH control (carbonic anhydrase
(CAIX)) and haemoglobin synthesis (erythropoietin)
(reviewed in [1]).
HIF-1a and its downstream genes such as VEGF and
CAIX are associated with advanced tumour stage, metas-
tases and a shorter survival in breast cancer [7-9]. The
HIF pathway also upregulates several genes that lead to a
proapoptotic phenotype, showing the complicated effects
of HIF in tumours. This paradox is observed in breast
cancer, where there appears to be a pivotal switch in the
HIF-induced gene for BNIP3 with progression from in
situ to invasive carcinoma [10]. This apparent dual action
of HIF is also emphasised in tumour models that have
demonstrated HIF is able to enhance both tumour
growth and angiogenesis, and also in data to show that
HIF has tumour-suppressive activity [11-13]. Since the
PHDs directly regulate and are regulated by HIF-1a,a n d
have been shown to control a number of other significant
intracellular factors including the adrenergic receptor
and NF-B [14], the above apparent opposing actions
potentially being due to the action of the PHDs.
Although many of the downstream HIF genes have
been studied extensively in breast tumours, however,
there are limited data for the PHDs [15]. We therefore
decided to assess the role of the PHDs in breast cancer
patients treated by neoadjuvant chemotherapy in the
setting of a phase II randomised trial. This assessment
provides the optimal opportunity for investigating the
effect of the PHDs, since HIF has been shown to med-
iate resistance to chemotherapy and radiotherapy and
biopsies can be compared both pre treatment and post
treatment. Our aims were to investigate the expression
of the regulatory hydroxylases, PHD1, PHD2 and PHD3
in tumours from patients at baseline and post treatment,
to correlate the expression of these factors with clinico-
pathological parameters, to explore the potential of
these factors as biomarkers for predicting tumour
response, and to explore the association between
changes in their expression and survival.
Materials and methods
Patients
Patients with T2-4 N0-1 breast cancer were recruited
into a randomised trial comparing single-agent epirubi-
cin (EPI arm) versus epirubicin plus tamoxifen (EPI-
TAM arm) as the primary systemic treatment [16].
Patients were accrued from January 1997 to December
2001. The study was approved by the Institutional Ethics
Committee. All patients gave written informed consent
to the diagnostic procedures, the proposed treatment,
and the biological evaluations. Two hundred and eleven
patients were enrolled: 105 were randomised to receive
epirubicin alone, and 106 were randomised to receive
epirubicin plus tamoxifen.
On first presentation, an incision biopsy was per-
formed on each patient and a small tissue sample (5 to
8 mm) was removed. Chemotherapy was started within
2 days of diagnosis. Patients in the EPI arm received
60 mg/m
2 epirubicin (Farmorubicina; Pharmacia, Milan,
Italy) by slow intravenous push on days 1 and 2;
whereas patients in the EPI-TAM arm received 60 mg/
m
2 epirubicin by slow intravenous push on days 1 and 2
and 30 mg tamoxifen (Kessar; Pharmacia) daily. Epirubi-
cin injections were repeated every 21 days for three or
four cycles before definitive surgery, whereas tamoxifen
was given continuously until definitive surgery. All
patients postoperatively received four cycles of the CMF
regimen: intravenous cyclophosphamide 600 mg/m
2,
intravenous methotrexate 40 mg/m
2, and intravenous 5-
fluorouracil 600 mg/m
2 on days 1 and 8, every 28 days
[11]. Patients with oestrogen receptor (ER)-positive pri-
mary tumour in both treatment arms received tamoxifen
(20 mg; that is, lower than the primary dose) starting
a f t e rs u r g e r y ,u pt op r o g r e s s i o no rf o ram a x i m u mo f
5 years. The median follow-up of patients was 53
months (August 2004; range, 13 to 95 months).
For treatment evaluation, the same clinician used a
calliper measuring the size of the primary tumour
monthly and manually the size of the axillary lymph
nodes, when appreciable. Response was assessed before
definitive surgery by clinical measurement of the
changes in the product of the two largest diameters
recorded in two successive evaluations. According to
World Health Organisation criteria, tumour progression
was defined as an increase of at least 25% in tumour
size; stable disease was defined as an increase <25% or a
reduction <50%; partial response was defined as tumour
shrinkage >50%; and complete response was defined as
the complete disappearance of all clinical signs of dis-
ease [17]. Pathologic complete response was defined as
the absence of neoplastic cells in the breast and in the
axillary lymph nodes. Surgery was planned after full
clinical reassessment. Quadrantectomy or modified
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association with full axillary node dissection. All patients
subjected to quadrantectomy underwent irradiation of
the residual breast (60 Gy delivered over 6 weeks).
Histopathologic grade and immunohistochemistry
Tumour grade was evaluated using the modified Bloom
and Richardson method. Immunohistochemical evalua-
tion was performed on paraffin-embedded tumour sam-
ples obtained at diagnosis and at definitive surgery. Bcl2,
p53, ER, progesterone receptor, and Ki67 staining were
carried out at the Pathology Unit of the Azienda Ospe-
daliera Istituti Ospitalieri of Cremona (Italy). The immu-
nohistochemical method used for routine markers is
fully described elsewhere [18].
Immunohistochemistry for PHD1, PHD2, and PHD3
was performed on sections from tissue microarrays con-
taining two 1 mm tumour cores taken from selected
morphologically representative tumour regions of each
paraffin-embedded breast tumour from both the initial
diagnostic incisional biopsy and from tumour remaining
at definitive surgery. Quality control was assessed on
each block by haematoxylin and eosin staining. The tis-
sue microarray sections were cut from each block at
4 μm thick intervals, dewaxed, placed through graded
alcohol and placed into water. Antigen retrieval was per-
formed in PT Link (Dako, Glostrup, Denmark) using
EnVision FLEX Target Retrieval Solution (Dako) - low
pH for PHD1, PHD2 and PHD3, and high pH for HIF-
1a - for 20 minutes at 100°C. VEGF required antigen
retrieval in pH 8 buffer (20 mM Tris/1 mM ethylenedia-
mine tetraacetic acid/10 mM sodium citrate) for 2 min-
utes in a pressure cooker. Endogenous peroxidase was
blocked with EnVision FLEX Peroxidase-Blocking
Reagent (Dako) before incubating the sections with
respective monoclonal antibodies, which were produced
by our group. The antibodies used to detect the hydro-
xylases were PHD1 (112), PHD2 (366G/76) and PHD3
(EG188e), which have previously been validated [15].
Slides were counterstained with haematoxylin and were
mounted.
Immunohistochemical scoring criteria
Staining for bcl2, p53 and Ki67 was scored by counting
the number of positively stained cells and was expressed
as a percentage of the total tumour cells (at least 1,000)
counted across several representative fields of the section
using a standard light microscope equipped with a 10 ×
10 square graticule. Reproducibility of counting was
assessed by a second investigator rescoring 10 slides
[19,20]. Cut-off values of the median values in each
group were compared. ER and progesterone receptor
were assessed in a semiquantitative fashion as described
previously by McCarty and colleagues [21], incorporating
both the intensity and distribution of specific staining.
The H-score was derived from the sum of the percen-
tages of positive-stained epithelial cells multiplied by the
weighted intensity of staining. Specimens were deemed
receptor positive if the H-score was greater than 100.
The immunohistochemical evaluation at mastectomy was
performed by the same pathologists, who remained
blinded as regards the disease response and the score
assessed at first biopsy.
Scoring for PHDs and VEGF was carried out accord-
ing to the previously used semiquantitative system
[15,22,23]. Although nuclear staining for the PHDs
occurred, this was at low frequency; scoring of the per-
centage of cells expressing the protein and of the inten-
sity of staining in the cytoplasm was therefore
performed for PHDs and VEGF. The scoring system for
intensity was: 0 = no staining, 1 = weak staining, 2 =
moderate staining, 3 = strong staining. The scoring sys-
tem for percentage was: 0 = no cells staining positive,
1 = <10% cells staining positive, 2 = 11 to 50% positive
cells, 3 = 51 to 80% positive cells, 4 = >80% positive
cells. At least 10% of cells needed to be stained to be
considered positive.
HIF-1a was scored only according to the presence
(1+) or absence (0) of nuclear expression. For CAIX
membrane staining, a score of 0 to 3 for the intensity
was given (0 = no staining, 1 = weak staining, 2 = mod-
erate staining, 3 = strong staining). For HIF and CAIX
any staining was considered positive, as hypoxia is fre-
quently focal. The missing cases indicated in Table 1
were not scored due to an absent core or an insufficient
number of tumour cells present in the tissue microarray
core (see Additional file 1).
Statistical methods
The chi-square test, the chi-square test for trend, and
Fisher’s Exact test were used when indicated to perform
comparisons of proportions. Kruskal-Wallis analysis of
variance was performed to compare continuous vari-
ables. Correlations between discrete variables were made
by Spearman’s R test for nonparametric data. Compari-
son of discrete data in matched tumour samples was
done using the Wilcoxon rank-sum test for paired data.
Overall survival was calculated from randomisation to
the occurrence of disease relapse or disease-related
death. Patients were censored if they were free from
recurrence and alive at the last follow-up period. Overall
survival curves were estimated using the Kaplan-Meier
method. Unadjusted differences in these estimates were
assessed with the log-rank test. All P values reported
were two-sided; P < 0.05 was considered statistically sig-
nificant. The Statistica for Windows software package
(version 8, StatSoft, Tulsa, OK, USA) was used for sta-
tistical analyses.
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Patient characteristics
One hundred and eighty-seven of the 211 (88.6%)
patients prospectively enrolled in the trial were evaluable
for PHD1, PHD2 and PHD3 staining. For the remaining
24 patients, insufficient material was available for the
study. Patient characteristics are shown in Table S1 in
Additional file 1. Ninety patients (48%) were randomised
to the EPI arm and 97 (52%) patients were randomised to
the EPI-TAM arm. PHD1 was evaluated at baseline exci-
sion in 176 (94%) tumours, PHD2 in 163 (87%) tumours
and PHD3 in 177 (94%) tumours. The corresponding
numbers of marker evaluation in matched tumour sam-
ples at biopsy and main tumour resection were 130 (69%)
tumours, 111 (59%) tumours and 127 (67.9%) tumours,
respectively (Figure S1 in Additional file 1). There were
12 patients who had a complete pathological response.
Relationship between tumours expressing PHD1, PHD2
and PHD3 at baseline and clinicopathologic variables
PHD1 was expressed in 47/176 (26.7%) tumours, PHD2
in 85/163 (52.2%) tumours and PHD3 in 69/177 (39%)
tumours at baseline. The distribution of expression dif-
fered for the different PHDs such that most positivity
for PHD1 was weak whereas for PHD2 and PHD3 the
dynamic range of expression was wider, being frequently
moderate to strong. Since the dynamic range (the range
of expression observed in this series) of the PHD1 was
low, PHD1 stratified as only negative (no staining) and
positive (>0 staining) whereas PHD2 and PHD3 were
stratified semiquantitatively (0 to 3). There was an
inverse relationship between both PHD1 and PHD3
positivity and high tumour grade (P <0 . 0 3a n dP =
0.04, respectively), but no significant relationship was
observed between PHD1 or PHD2 expression and
HER2, T status, N status, p53, bcl2, Ki67, ER or proges-
terone receptor (P >0 . 0 5 ;s e eT a b l e sS 2t oS 4i nA d d i -
tional file 1). PHD3 expression did not show any
relationship with any of the clinical and biological para-
meters considered. No association was observed
between tumours that express all PHDs and tumour
size, grade, nodal status, ER, progesterone receptor,
HER2, p53, ki67, bcl2 or ki67 (all P > 0.05; see Table S5
in Additional file 1).
Relationship of tumours expressing PHD1, PHD2 and
PHD3 at baseline with HIF-1a and HIF-induced markers
There was a significant positive relationship between
HIF-1a and PHD1 (P = 0.002) and PHD3 (P < 0.05) but
not PHD2 (P = 0.41). There was a significant positive
relationship between VEGF and PHD1 (P < 0.008) and
PHD3 (P = 0.001) but not PHD2 (P =0 . 0 9 ) .T h e r ew a s
no significant association between CAIX and PHD1,
PHD2 or PHD3 (all P > 0.05).
Effect of treatment on tumours expressing PHD1, PHD2
and PHD3
PHD1, PHD2 and PHD3 expression was significantly
increased after therapy with epirubicin either alone or in
combination with tamoxifen (P < 0.0001, P < 0.0001 and
P < 0.0001) (Table 2). PHD1 positivity was thus present
in 43/130 baseline tumour samples (33.1%) but in 111/
130 tumour samples (85.4%) at residual tumour histol-
ogy. Similar results were obtained for PHD2, where 49/
111 (44.1%) tumour samples were positive at baseline
and 98/111 (88.3%) tumour samples were positive after
chemotherapy. PHD3 was positive in 58/127 (45.6%)
tumour samples at baseline and in 119/127 (93.7%)
Table 1 Distribution of immunoscoring for hypoxia
pathway factors and cut-off values used in
semiquantitative analyses
Factor n (%)
Hypoxia-inducible factor-1a
0 33 (19.3%)
1 100 (58.5%)
2 38 (22.2%)
Missing 16
Vascular endothelial growth factor
0 32 (20.0%)
1 39 (24.4%)
2 37 (23.1%)
4 52 (32.5%)
Missing 27
Carbonic anhydrase IX
0 125 (75.3%)
1 20 (12.1%)
≥2 21 (12.6%)
Missing 21
Prolyl hydroxylase 1
0 129 (73.3%)
1 43 (24.4%)
2 3 (1.7%)
3 1 (0.6%)
Missing 11
Prolyl hydroxylase 2
0 78 (47.8%)
1 51 (31.3%)
2 30 (18.4%)
3 4 (2.4%)
Missing 24
Prolyl hydroxylase 3
0 108 (61.0%)
1 53 (29.9%)
2 15 (8.5%)
3 1 (0.6%)
Missing 10
Data refer to the number of tumours positive in each intensity score category.
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nificant difference in PHD changes between the treat-
ment arms, or between tumours stratified according to
the ER status and treatment administered in ER-positive
patients (all P > 0.05).
Predictive role of PHD1, PHD2 and PHD3 expression and
treatment activity
The relationship between baseline PHD1, PHD2 and
PHD3 status and treatment response is depicted in
Table 3. PHD1 and PHD3 positivity showed a progres-
sive decrease according to the grade of response
obtained, but this failed to attain statistical significance
(P =0 . 1 5a n dP = 0.14, respectively). PHD2 positivity
showed a similar but increasing nonsignificant trend
with tumour response (P = 0.17). There was no signifi-
cant difference in response in tumours that expressed
all PHDs (P = 0.59).
Prognostic role of PHD1, PHD2 and PHD3
There was no significant difference in disease-free survi-
val at baseline histology or residual histology for patients
with tumours expressing PHD1 (P =0 . 1 7a n dP =0 . 2 3 ,
respectively), PHD2 (P = 0.91 and P = 0.11, respectively)
or PHD3 (P =0 . 4 2a n dP = 0.12, respectively). There
was no significant difference in disease-free survival
when stratifying patients by their tumours expressing all
PHDs either at baseline (P = 0.76) or on residual histol-
ogy (P = 0.22).
Discussion
HIF signalling is critically important for cell survival in
low-oxygen environments, as occurs in tumours [24]. HIF
is rapidly degraded after hydroxylation by the PHDs in the
presence of molecular oxygen [25]. We hypothesised that
tumours with high baseline levels of the PHDs and/or that
are able to induce PHD after chemotherapy could modu-
late HIF-1a levels and thereby alter HIF signalling. The
Table 2 PHD1, PHD2 and PHD3 expression before and
after treatment in matched cases
Before n (%) After n (%) P value
PHD1 Overall (n = 130)
0 87 (66.9) 19 (14.6) 0.0000
1 39 (30.0) 68 (53.3)
2 3 (2.3) 36 (27.7)
3 1 (0.8) 7 (5.4)
EPI (n = 64)
0 40 (62.5) 8 (12.5) 0.0000
1 23 (35.9) 32 (50.0)
2 1 (1.6) 23 (35.9)
3 1 (1.6)
EPI-TAM (n = 66)
0 47 (71.2) 11 (16.7) 0.0000
1 16 (24.2) 36 (54.5)
2 2 (3.0) 13 (19.7)
3 1 (1.5) 6 (9.1)
PHD2 Overall (n = 111)
0 62 (55.9%) 13 (11.7%) 0.0000
1 31 (27.9%) 15 (13.6%)
2 16 (14.4%) 43 (38.7%)
3 2 (1.8%) 40 (36.0%)
EPI (n = 59)
0 31 (52.5) 5 (8.5) 0.0000
1 16 (27.1) 6 (10.2)
2 10 (16.9) 22 (37.3)
3 2 (3.4) 26 (44.1)
EPI-TAM (n = 52)
0 31 (59.6) 8 (15.4) 0.0000
1 15 (28.8) 9 (17.3)
2 6 (11.5) 21(40.4)
3 0 14 (26.9)
PHD3 Overall (n = 127)
0 69/127 (54.3%) 8/127 (6.3%) 0.00
1 46/127 (36.2%) 47/127 (37.0%)
2 12/127 (9.4%) 47/127 (37.0%)
3 0.00 25/127 (19.7%)
EPI (n = 63)
0 29/63(46.0%) 3/63(4.8%) 0.00
1 27/63 (42.8%) 22/63 (34.9%)
2 7/63 (11.1%) 23/63 (36.5%)
3 0.00 15/63 (23.8%)
EPI-TAM (n = 64)
0 40/64 (62.5%) 5/64 (7.8%) 0.00
1 19/64 (29.7%) 25/64 (39.1%)
2 5/64 (7.8%) 24/64 (37.5%)
3 0.00 10/64 (15.6%)
EPI, epirubicin treatment; EPI-TAM, epirubicin plus tamoxifen treatment; PHD,
prolyl hydroxylase.
Table 3 Predictive role of baseline PHD1, PHD2 and
PHD3 positivity for disease response in overall cases
No
response
Partial
Response
Complete
Response
P
value
PHD1-
positive
13/38
(34.2%)
28/105 (26.7%) 6/32 (18.7%) 0.15
PHD2-
positive
18/35
(51.4%)
45/97 (46.4%) 21/30 (70.0%) 0.17
PHD3-
positive
19/38
(50.0%)
39/105 (37.1%) 11/33 (33.3%) 0.14
One patient was not assessable for disease response due to treatment refusal
after one cycle.
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the tumour and may be useful as a predictive marker. We
also hypothesised that certain chemotherapeutic agents
may be able to alter PHDs expression in tumours either
directly through their effect on tumour cells or indirectly
through changes in vascularity and oxygen delivery, and
thereby also modulate HIF activity.
We observed frequent expression of the PHDs in inva-
sive breast carcinoma that ranged from ~25 to 50% of
cancer cells, suggesting that the PHDs are important in
human breast cancer. Expression of PHD2 and PHD3
was stronger than PHD1, which is in keeping with these
being the most potent isoforms that regulate HIF-1a
and HIF-2a [26] - although PHD1 (and PHD3) may
cooperate with PHD2, the major oxygen sensor [27].
Although PHD1 levels are regulated by oestrogen [28],
we observed no association between ER and PHD1
either at baseline or in patients treated with tamoxifen -
suggesting this is not a major control mechanism for
PHD1 in breast cancer. This observation also supports
the notion of PHD1 not having a significant role in
breast tumorigenesis. Nevertheless, PHD1 and PHD3
were significantly positively associated with HIF-1a and
the HIF-1a-regulated gene VEGF. It is recognised that
PHD2 and PHD3 expression is modulated by directly by
hypoxia, but less appreciated is that PHD1 levels may be
altered through suppression of its mRNA under hypoxia
[29]. This is in keeping with the upregulation of all
PHDs in the breast tumours in this series. Although one
might anticipate that elevated levels of PHDs would lead
directly to lower HIF through proteosomal degradation,
the final effect is not predictable because, if chronic
tumour hypoxia still persists, PHD hydroxylation will be
abrogated. Furthermore, even in the presence of oxygen,
there is some evidence to suggest that the scaffold pro-
tein map organiser 1 may block the hydroxylated HIF-
1a from entering the degradation pathway, thus retain-
ing some of its transcriptional activity [30]. Other
mechanisms may also be present that may enable HIF
to escape proteosomal degradation, such as generation
of reactive oxygen species [31]. The absence of a corre-
lation of PHDs with CAIX is likely to be due to its sig-
nificantly longer half-life than HIF-1a,i nt h eo r d e ro f
~35 hours [32]. This is because both markers need to
be present at the same time for an association to be
identified. Thus, unlike HIF-1a that has a half-life mea-
sured in minutes, the prolonged half-life of CAIX means
it would remain in the tumour when other proteins
with a shorter half-life are no longer present.
We also observed a significant increase all PHDs post
chemotherapy in both trial arms. This increase is poten-
tially hypoxically mediated, since epirubicin has been
reported to result in a reduction of blood flow and to
have anti-angiogenic effects [33]. Furthermore, despite
all PHDs generally increasing post chemotherapy, there
was a general trend for upregulation of PHD2 and
downregulation of PHD1 and PHD3 to be associated
with response. Although this differential regulation is
unexpected, one should note that although widely
expressed they have differing tissue distributions (for
example, PHD3 is highly expressed in the heart whereas
PHD1 is highly expressed in the testes) and that it is
unclear why the three different isoforms exist and what
their specific or overlapping activities might be in HIF-
related and HIF-independent biology.
Although all three PHDs may have similar roles in
some biological functions, they thus also have function
specific to individual PHDs. For example, PHD2 appears
to be the sole PHD responsible for myocardial develop-
ment since Phd2
-/- knockouts are embryonic lethal and
the myocardium is severely underdeveloped, amongst
other major defects [34]. The same phenotype is not
observed with Phd1
-/- or Phd3
-/- knockouts. Further-
more, PHD3 is the only PHD that appears to mediate
apoptosis [35], the latter requiring the catalytic activity
of PHD3 (as cells are not rescued by HIF-1a and/or
HIF-2a), suggesting that PHD3 has non-HIF targets
[35]. The effects of PHDs, however, also appear to be
cell type specific. The PHDs thus promote cell survival
rather than cell death in chondrocytes. A further level of
complexity is through the ability of particular PHDs to
modulate HIF-independent pathways. PHD1, through
hydroxylation of IB kinase-b, thus fails to result in dis-
association of IBf r o mN F - B, altering this transcrip-
tional response [36].
The above data support the notion that the resultant
decrease in PHD1 could result in a tumour responding
via HIF-independent mechanisms. Loss of PHD1 may
thus be anticipated to downregulate cyclin D1 levels and
suppress mammary tumour proliferation [37]. However,
the biological effect of the expression of particular
PHDs in individual tumours may also depend on the
type of hypoxia (acute and/or chronic) to which it is
exposed. Desensitisation and loss of HIF-1a (and HIF-
2a) via hydroxylation by the PHDs has thus been
reported to occur under long-term hypoxia, as intracel-
lular oxygen availability is increased by inhibiting mito-
chondrial respiration [38].
Conclusions
PHDs are frequently expressed in breast cancer, with
PHD2 and PHD3 being the dominant isoforms. The asso-
ciation with HIF and VEGF and their upregulation on
therapy in residual tumour suggests the PHDs may be a
suitable target for anticancer therapy. Conflicting in vivo
preclinical evidence for their differing functional effects in
a variety of pathways, however, demonstrates that further
preclinical work is needed to resolve these issues.
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Additional file 1: Supplementary data. Table S1 presenting patient
characteristics. Table S2 presenting the distribution of clinical and
immunohistochemical parameters according to PHD1 expression (0, >0).
Table S3 presenting the distribution of clinical and immunohistochemical
parameters according to PHD2 expression (0, 1, ≥2). Table S4 presenting
the distribution of clinical and immunohistochemical parameters
according to PHD3 expression (0, 1, ≥2). Table S5 presenting the
distribution of clinical and immunohistochemical parameters according
to PHD (all positive). Figure S1 showing a consort diagram.
Abbreviations
CAIX: carbonic anhydrase IX; ER: oestrogen receptor; HIF: hypoxia-inducible
factor; NF: nuclear factor; PHD: prolyl hydroxylase; VEGF: vascular endothelial
growth factor.
Acknowledgements
The present study was supported by the Victorian Breast Cancer Research
Consortium, Australia, the Association Amici dell’Ospedale di Cremona,
APOM Onlus, the Regione Piemonte, Progetto Ricerca Finalizzata type 3 no
24723, Cancer Research UK and the Oxford NIHR Biomedical Research
Programme.
Author details
1Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, Victoria
3002, Australia.
2Unità di Patologia Mammaria - Breast Cancer Unit and
Anatomia Patologica, Azienda Instituti Ospitalieri di Cremona, Viale
Concordia 1, 26100 Cremona, Italy.
3Oncologia Medica, Dipartimento di
Scienze Cliniche e Biologiche, Università di Torino Azienda Ospedaliera San
Luigi di Orbassano, Regione Gonzole 10, Orbassano 10043, Italy.
4Molecular
Oncology Laboratories, Weatherall Institute of Molecular Medicine, University
of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, UK.
Authors’ contributions
SBF contributed to study conception and design, data analysis and
interpretation, and writing the manuscript. DG contributed to study
conception and design, collection and assembly of data, data analysis and
interpretation, and writing the manuscript. AB contributed to study
conception and design, collection and assembly of data, data analysis and
interpretation, and writing the manuscript. MPB contributed to study
conception and design, and collection and assembly of data. LC, SA, AB and
LD contributed to the provision of study materials or patients. SB, GA, and
TM contributed to the provision of study materials or patients, and
collection and assembly of data. MM contributed to study conception and
design, the provision of study materials or patients, and collection and
assembly of data. ABo contributed to study conception and design. ALH
contributed to data analysis and interpretation, and writing the manuscript.
All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 5 August 2010 Revised: 12 November 2010
Accepted: 3 February 2011 Published: 3 February 2011
References
1. Harris AL: Hypoxia - a key regulatory factor in tumour growth. Nat Rev
Cancer 2002, 2:38-47.
2. Generali D, Berruti A, Brizzi MP, Campo L, Bonardi S, Wigfield S, Bersiga A,
Allevi G, Milani M, Aguggini S, Gandolfi V, Dogliotti L, Bottini A, Harris AL,
Fox SB: Hypoxia-inducible factor-1α expression predicts a poor response
to primary chemoendocrine therapy and disease-free survival in primary
human breast cancer. Clin Cancer Res 2006, 12:4562-4568.
3. Maxwell PH: The HIF pathway in cancer. Semin Cell Dev Biol 2005,
16:523-530.
4. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ,
Kriegsheim Av, Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH,
Pugh CW, Ratcliffe PJ: Targeting of HIF-α to the von Hippel-Lindau
ubiquitylation complex by O2-regulated prolyl hydroxylation. Science
2001, 292:468-472.
5. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME,
Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ: The tumour suppressor
protein VHL targets hypoxia-inducible factors for oxygen-dependent
proteolysis. Nature 1999, 399:271-275.
6. Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O’Rourke J, Mole DR,
Mukherji M, Metzen E, Wilson MI, Dhanda A, Tian YM, Masson N,
Hamilton DL, Jaakkola P, Barstead R, Hodgkin J, Maxwell PH, Pugh CW,
Schofield CJ, Ratcliffe PJ: C. elegans EGL-9 and mammalian homologs
define a family of dioxygenases that regulate HIF by prolyl
hydroxylation. Cell 2001, 107:43-54.
7. Bos R, van der Groep P, Greijer AE, Shvarts A, Meijer S, Pinedo HM,
Semenza GL, van Diest PJ, van der Wall E: Levels of hypoxia-inducible
factor-1α independently predict prognosis in patients with lymph node
negative breast carcinoma. Cancer 2003, 97:1573-1581.
8. Dales JP, Garcia S, Meunier-Carpentier S, Andrac-Meyer L, Haddad O,
Lavaut MN, Allasia C, Bonnier P, Charpin C: Overexpression of hypoxia-
inducible factor HIF-1α predicts early relapse in breast cancer:
retrospective study in a series of 745 patients. Int J Cancer 2005,
116:734-739.
9. Chia SK, Wykoff CC, Watson PH, Han C, Leek RD, Pastorek J, Gatter KC,
Ratcliffe P, Harris AL: Prognostic significance of a novel hypoxia-regulated
marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol
2001, 19:3660-3668.
10. Tan EY, Campo L, Han C, Turley H, Pezzella F, Gatter KC, Harris AL, Fox SB:
BNIP3 as a progression marker in primary human breast cancer;
opposing functions in in situ versus invasive cancer. Clin Cancer Res 2007,
13:467-474.
11. Ryan HE, Lo J, Johnson RS: HIF-1 α is required for solid tumor formation
and embryonic vascularization. EMBO J 1998, 17:3005-3015.
12. Ryan HE, Poloni M, McNulty W, Elson D, Gassmann M, Arbeit JM,
Johnson RS: Hypoxia-inducible factor-1α is a positive factor in solid
tumor growth. Cancer Res 2000, 60:4010-4015.
13. Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M,
Neeman M, Bono F, Abramovitch R, Maxwell P, Koch CJ, Ratcliffe P,
Moons L, Jain RK, Collen D, Keshert E: Role of HIF-1α in hypoxia-mediated
apoptosis, cell proliferation and tumour angiogenesis. Nature 1998,
394:485-490.
14. Chan DA, Kawahara TL, Sutphin PD, Chang HY, Chi JT, Giaccia AJ: Tumor
vasculature is regulated by PHD2-mediated angiogenesis and bone
marrow-derived cell recruitment. Cancer Cell 2009, 15:527-538.
15. Soilleux EJ, Turley H, Tian YM, Pugh CW, Gatter KC, Harris AL: Use of novel
monoclonal antibodies to determine the expression and distribution of
the hypoxia regulatory factors PHD-1, PHD-2, PHD-3 and FIH in normal
and neoplastic human tissues. Histopathology 2005, 47:602-610.
16. Bottini A, Berruti A, Brizzi MP, Bersiga A, Generali D, Allevi G, Aguggini S,
Bolsi G, Bonardi S, Tondelli B, Vana F, Tampellini M, Alquati P, Dogliotti L:
Cytotoxic and antiproliferative activity of the single agent epirubicin
versus epirubicin plus tamoxifen as primary chemotherapy in human
breast cancer: a single-institution phase III trial. Endocr Relat Cancer 2005,
12:383-392.
17. World Health Organization: WHO Handbook for Reporting Results of Cancer
Treatment WHO Offset Publication. Geneva, Switzerland: World Health
Organisation; 1978.
18. Generali D, Buffa FM, Berruti A, Brizzi MP, Campo L, Bonardi S, Bersiga A,
Allevi G, Milani M, Aguggini S, Papotti M, Dogliotti L, Bottini A, Harris AL,
Fox SB: Phosphorylated ERα, HIF-1α, and MAPK signaling as predictors of
primary endocrine treatment response and resistance in patients with
breast cancer. J Clin Oncol 2009, 27:227-234.
19. Bottini A, Berruti A, Bersiga A, Brizzi MP, Brunelli A, Gorzegno G, DiMarco B,
Aguggini S, Bolsi G, Cirillo F, Filippini L, Betri E, Bertoli G, Alquati P,
Dogliotti L: p53 but not bcl-2 immunostaining is predictive of poor
clinical complete response to primary chemotherapy in breast cancer
patients. Clin Cancer Res 2000, 6:2751-2758.
20. Bottini A, Berruti A, Bersiga A, Brizzi MP, Bruzzi P, Aguggini S, Brunelli A,
Bolsi G, Allevi G, Generali D, Betri E, Bertoli G, Alquati P, Dogliotti L:
Relationship between tumour shrinkage and reduction in Ki67
expression after primary chemotherapy in human breast cancer. Br J
Cancer 2001, 85:1106-1112.
Fox et al. Breast Cancer Research 2011, 13:R16
http://breast-cancer-research.com/content/13/1/R16
Page 7 of 821. McCarty KS Jr, Miller LS, Cox EB, Konrath J, McCarty KS Sr: Estrogen
receptor analyses. Correlation of biochemical and immunohistochemical
methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med
1985, 109:716-721.
22. Boddy JL, Fox SB, Han C, Campo L, Turley H, Kanga S, Malone PR, Harris AL:
The androgen receptor is significantly associated with vascular
endothelial growth factor and hypoxia sensing via hypoxia-inducible
factors HIF-1a, HIF-2a, and the prolyl hydroxylases in human prostate
cancer. Clin Cancer Res 2005, 11:7658-7663.
23. Couvelard A, O’Toole D, Turley H, Leek R, Sauvanet A, Degott C,
Ruszniewski P, Belghiti J, Harris AL, Gatter K, Pezzella F: Microvascular
density and hypoxia-inducible factor pathway in pancreatic endocrine
tumours: negative correlation of microvascular density and VEGF
expression with tumour progression. Br J Cancer 2005, 92:94-101.
24. Ruan K, Song G, Ouyang G: Role of hypoxia in the hallmarks of human
cancer. J Cell Biochem 2009, 107:1053-1062.
25. Semenza GL: Regulation of cancer cell metabolism by hypoxia-inducible
factor 1. Semin Cancer Biol 2009, 19:12-16.
26. Henze AT, Riedel J, Diem T, Wenner J, Flamme I, Pouyseggur J, Plate KH,
Acker T: Prolyl hydroxylases 2 and 3 act in gliomas as protective
negative feedback regulators of hypoxia-inducible factors. Cancer Res
2009, 70:357-366.
27. Minamishima YA, Moslehi J, Padera RF, Bronson RT, Liao R, Kaelin WG Jr: A
feedback loop involving the Phd3 prolyl hydroxylase tunes the
mammalian hypoxic response in vivo. Mol Cell Biol 2009, 29:5729-5741.
28. Appelhoff RJ, Tian YM, Raval RR, Turley H, Harris AL, Pugh CW, Ratcliffe PJ,
Gleadle JM: Differential function of the prolyl hydroxylases PHD1, PHD2,
and PHD3 in the regulation of hypoxia-inducible factor. J Biol Chem 2004,
279:38458-38465.
29. Tian YM, Mole DR, Ratcliffe PJ, Gleadle JM: Characterization of different
isoforms of the HIF prolyl hydroxylase PHD1 generated by alternative
initiation. Biochem J 2006, 397:179-186.
30. Fong GH, Takeda K: Role and regulation of prolyl hydroxylase domain
proteins. Cell Death Diff 2008, 15:635-641.
31. Kaelin WG Jr, Ratcliffe PJ: Oxygen sensing by metazoans: the central role
of the HIF hydroxylase pathway. Mol Cell 2008, 30:393-402.
32. Sobhanifar S, Aquino-Parsons C, Stanbridge EJ, Olive P: Reduced expression
of hypoxia-inducible factor-1α in perinecrotic regions of solid tumors.
Cancer Res 2005, 65:7259-7266.
33. Maragoudakis ME, Peristeris P, Missirlis E, Aletras A, Andriopoulou P,
Haralabopoulos G: Inhibition of angiogenesis by anthracyclines and
titanocene dichloride. Ann N Y Acad Sci 1994, 732:280-293.
34. Takeda K, Ho VC, Takeda H, Duan LJ, Nagy A, Fong GH: Placental but not
heart defects are associated with elevated hypoxia-inducible factor
alpha levels in mice lacking prolyl hydroxylase domain protein 2. Mol
Cell Biol 2006, 26:8336-8346.
35. Lee S, Nakamura E, Yang H, Wei W, Linggi MS, Sajan MP, Farese RV,
Freeman RS, Carter BD, Kaelin WG Jr, Schlisio S: Neuronal apoptosis linked
to EglN3 prolyl hydroxylase and familial pheochromocytoma genes:
developmental culling and cancer. Cancer Cell 2005, 8:155-167.
36. Cummins EP, Berra E, Comerford KM, Ginouves A, Fitzgerald KT,
Seeballuck F, Godson C, Nielsen JE, Moynagh P, Pouyssegur J, Taylor CT:
Prolyl hydroxylase-1 negatively regulates IκB kinase-β, giving insight
into hypoxia-induced NFκB activity. Proc Natl Acad Sci USA 2006,
103:18154-18159.
37. Zhang Q, Gu J, Li L, Liu J, Luo B, Cheung HW, Boehm JS, Ni M, Geisen C,
Root DE, Polyak K, Brown M, Richardson AL, Hahn WC, Kaelin WG Jr,
Bommi-Reddy A: Control of cyclin D1 and breast tumorigenesis by the
EglN2 prolyl hydroxylase. Cancer Cell 2009, 16:413-424.
38. Ginouves A, Ilc K, Macias N, Pouyssegur J, Berra E: PHDs overactivation
during chronic hypoxia ‘desensitizes’ HIFα and protects cells from
necrosis. Proc Natl Acad Sci USA 2008, 105:4745-4750.
doi:10.1186/bcr2825
Cite this article as: Fox et al.: The prolyl hydroxylase enzymes are
positively associated with hypoxia-inducible factor-1a and vascular
endothelial growth factor in human breast cancer and alter in response
to primary systemic treatment with epirubicin and tamoxifen. Breast
Cancer Research 2011 13:R16.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Fox et al. Breast Cancer Research 2011, 13:R16
http://breast-cancer-research.com/content/13/1/R16
Page 8 of 8